Enhancement of Biliary Carcinogenesis in Hamsters by Cholecystokinin

Overview

Journal World J Surg

Publisher Wiley

Specialty General Surgery

Date 1995 Nov 1

PMID 8553677

Authors

Y Ikematsu

T Tomioka

Y Tajima

T Tsunoda

T Kanematsu

Affiliations

Soon will be listed here.

Abstract

We recently developed a new model for rapid and reproducible induction of biliary carcinoma in hamsters. In the present study, we evaluated the effects of cholecystokinin (CCK), which has a trophic action on the gastrointestinal tract and on the pancreaticobiliary system, on biliary carcinogenesis in this hamster model. Hamsters treated with N-nitrosobis (2-oxopropyl) amine (BOP) were divided into four groups: In Group I, hydrolyzed gelatin, a solvent of CCK, was injected subcutaneously. In Groups II and III, CCK 2.5 and 25 microgram/kg were administered, respectively. In Group IV loxiglumide, a CCK receptor antagonist, was administered. CCK significantly promoted the carcinogenetic effect of BOP in the intra- and extrahepatic bile ducts but not in the gallbladder or pancreas. Loxiglumide exerted an inhibitory effect on carcinogenesis in the intrahepatic bile duct.

References

Solomon T, Petersen H, Elashoff J, GROSSMAN M . Interaction of caerulein and secretin on pancreatic size and composition in rat. Am J Physiol. 1978; 235(6):E714-9. DOI: 10.1152/ajpendo.1978.235.6.E714. View

Scarpelli D, Rao M, Subbarao V . Augmentation of carcinogenesis by N-nitrosobis(2-oxopropyl)amine administered during S phase of the cell cycle in regenerating hamster pancreas. Cancer Res. 1983; 43(2):611-6. View

Meijers M, Lamers C, Rovati L, Jansen J, Woutersen R . Effects of bombesin on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters. Cancer Lett. 1991; 59(1):45-50. DOI: 10.1016/0304-3835(91)90134-4. View

Tsuchiya R, Harada N, Ito T, Furukawa M, Yoshihiro I . Malignant tumors in choledochal cysts. Ann Surg. 1977; 186(1):22-8. PMC: 1396188. DOI: 10.1097/00000658-197707000-00004. View

Pour P, Lawson T, Helgeson S, Donnelly T, Stepan K . Effect of cholecystokinin on pancreatic carcinogenesis in the hamster model. Carcinogenesis. 1988; 9(4):597-601. DOI: 10.1093/carcin/9.4.597. View

Flanigan P . Biliary cysts. Ann Surg. 1975; 182(5):635-43. PMC: 1344050. DOI: 10.1097/00000658-197511000-00017. View

Putz P, Williams G . Proliferative changes in the epithelium of the human lithiasic gallabladder. J Natl Cancer Inst. 1978; 60(2):283-7. DOI: 10.1093/jnci/60.2.283. View

Meijers M, Lamers C, Rovati L, Jansen J, Woutersen R . Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters. Carcinogenesis. 1990; 11(12):2223-6. DOI: 10.1093/carcin/11.12.2223. View

Tajima Y, Eto T, Tsunoda T, Tomioka T, Inoue K, Fukahori T . Induction of extrahepatic biliary carcinoma by N-nitrosobis(2-oxopropyl)amine in hamsters given cholecystoduodenostomy with dissection of the common duct. Jpn J Cancer Res. 1994; 85(8):780-8. PMC: 5919560. DOI: 10.1111/j.1349-7006.1994.tb02948.x. View

10.

Setnikar I, Bani M, Cereda R, Chiste R, Makovec F, Pacini M . Anticholecystokinin activities of loxiglumide. Arzneimittelforschung. 1987; 37(10):1168-71. View

11.

Douglas B, Woutersen R, Jansen J, Rovati L, Lamers C . Study into the role of cholecystokinin in bombesin-stimulated pancreatic growth in rats and hamsters. Eur J Pharmacol. 1989; 161(2-3):209-14. DOI: 10.1016/0014-2999(89)90845-5. View

12.

Konturek J, Konturek S, Kurek A, Bogdal J, OLEKSY J, Rovati L . CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man. Gut. 1989; 30(8):1136-42. PMC: 1434177. DOI: 10.1136/gut.30.8.1136. View

13.

Douglas B, Woutersen R, Jansen J, de Jong A, Rovati L, Lamers C . Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. Gastroenterology. 1989; 96(2 Pt 1):462-9. DOI: 10.1016/0016-5085(89)91572-2. View

14.

Malesci A, De Fazio C, Festorazzi S, Bonato C, Valentini A, Tacconi M . Effect of loxiglumide on gallbladder contractile response to cerulein and food in humans. Gastroenterology. 1990; 98(5 Pt 1):1307-10. DOI: 10.1016/0016-5085(90)90349-6. View

15.

Liddle R, Goldfine I, Williams J . Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology. 1984; 87(3):542-9. View

16.

Barrowman J . The tropic action of gastro-intestinal hormones. Digestion. 1975; 12(2):92-104. DOI: 10.1159/000197659. View

17.

Nio Y, Tsubono M, Morimoto H, Kawabata K, Masai Y, Hayashi H . Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice. Cancer. 1993; 72(12):3599-606. DOI: 10.1002/1097-0142(19931215)72:12<3599::aid-cncr2820721209>3.0.co;2-8. View

18.

Tsunoda T, Eto T, Koga M, Tomioka T, Motoshima K, Yamaguchi T . Early carcinoma of the extrahepatic bile duct. Jpn J Surg. 1989; 19(6):691-8. DOI: 10.1007/BF02471720. View

19.

Schwarzendrube J, Niederau M, Luthen R, Niederau C . Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers. Gastroenterology. 1991; 100(6):1683-90. DOI: 10.1016/0016-5085(91)90670-g. View

20.

Evers B, Gomez G, Townsend Jr C, Rajaraman S, Thompson J . Endogenous cholecystokinin regulates growth of human cholangiocarcinoma. Ann Surg. 1989; 210(3):317-22; discussion 322-3. PMC: 1357994. DOI: 10.1097/00000658-198909000-00007. View